FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

Colorectal cancer patients with BRAF-mutant tumors have a more aggressive, rapidly progressing disease that is in critical need of novel therapeutic approaches. Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving standard-of-care therapy is approximately tw...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Lim, Bora, Scicchitano, Angelique, Beachler, Cheryl, Gusani, Niraj, Sarwani, Nabeel, Yang, Zhaohai, Staveley-O’Carroll, Kevin, Ashkenazi, Avi, Portera, Chia, El-Deiry, Wafik S
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2013
Teme:
Bedside to Bench Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841210/
https://ncbi.nlm.nih.gov/pubmed/23792567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25310
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki